Letter to the Editor
FGF 23 and risk of all-cause mortality and cardiovascular events: A meta-analysis of prospective cohort studies,☆☆,

https://doi.org/10.1016/j.ijcard.2014.08.125Get rights and content

Section snippets

Conflict of interest

The authors report no relationships that could be construed as a conflict of interest.

First page preview

First page preview
Click to open first page preview

References (26)

  • M. Plischke et al.

    Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure

    Eur J Clin Invest

    (2012)
  • D. Prie et al.

    Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list

    PLoS One

    (2013)
  • H. Sugimoto et al.

    Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients

    Int Urol Nephrol

    (2014)
  • Cited by (5)

    • Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation

      2015, Nefrologia
      Citation Excerpt :

      In a population study, non-sudden cardiac death is found to be associated with high FGF-2330. Recently in the meta-analysis of prospective cohort studies, a relationship between FGF-23 and all-cause mortality and cardiovascular events was observed31. However, additional studies are required to determine FGF-23 receptors that mediate the cardiac effects of FGF-23.

    Funding/support: None.

    ☆☆

    Ethical review: Not applicable.

    Statement of authorship: All authors have contributed to the critical revision of the manuscript for important intellectual content.

    View full text